about
Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint ApproachIntrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutationsCIViC databaseThree generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancerNext-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceOsimertinib making a breakthrough in lung cancer targeted therapyStructure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors.A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistanceOne reporter for in-cell activity profiling of majority of protein kinase oncogenes.Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.New paradigms in clonal evolution: punctuated equilibrium in cancer.Latest Advances Towards Ras Inhibition: A Medicinal Chemistry Perspective.Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.Pharmacological management of relapsed/refractory NSCLC with chemical drugs.Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer.Circulating tumor cells and CDX models as a tool for preclinical drug developmentClinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients.Current Landscape of Targeted Therapy in Lung Cancer.Pyrimidine containing epidermal growth factor receptor kinase inhibitors: Synthesis and biological evaluation.Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis.Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance.Lessons to be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer.A comparison of QuantStudio™ 3D Digital PCR and ARMS-PCR for measuring plasma EGFR T790M mutations of NSCLC patients.Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients.Targeted therapy of brain metastases: latest evidence and clinical implications.Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.Structural insights into drug development strategy targeting EGFR T790M/C797S.Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis.Efficacy and Safety of Osimertinib in a Hemodialysis Patient With Advanced Non-Small Cell Lung Cancer.Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant.Extending the curve: survival of EGFR-mutated lung cancer patients in the 21st century.Osimertinib: A Novel Therapeutic Option for Overcoming T790M Mutations in Non-Small Cell Lung Cancer.Addressing the challenges of applying precision oncology.Characterization of Covalent-Reversible EGFR Inhibitors.Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective
P2860
Q24672143-E7ADB7F3-C614-45D9-887E-A59C1B7E3FBBQ26744339-3F9BC97E-9FE3-4C3C-87C4-F61DAE7BD553Q27612411-33530699-4E52-40A0-879E-F94CD5775DD6Q28075704-33E029A8-72F6-49DD-9C3E-49631FF40396Q28079320-0F45169C-3550-4BF7-9166-B2DADB7B22FEQ28079689-2FC2EB83-AF57-4CE5-B44D-46714BA2FA2BQ33812445-815944E8-CD59-48E9-8F47-2117A47834BFQ37609221-1116EFA9-2F54-4453-B02C-6E2ECA7E3822Q37643703-4B05908A-C79A-4421-9539-F377A97529E3Q38838757-4B2819D0-1BBB-4942-BB94-2E25A6F6486AQ38860529-BCBA4B37-48DC-4FF9-B856-0B0A5401976EQ38956084-0B7AADFF-DBE9-4704-A669-0B99E64C9DB9Q38989374-209F686B-5EF8-4028-BAA0-B75980E47425Q39095285-7A4154D4-4DE4-478B-B92F-4DCE49F1DDADQ39220897-00DD62C3-E7EA-44C7-9EDD-2AD6D00AE9A0Q39436392-5730A71F-F7D0-485F-B996-29133858C2FCQ41605022-C02C936E-BBF0-49E0-9B74-359F7993E957Q42279529-C9BB0D17-3628-4654-B21C-046BFEEACA9AQ46034707-E7BA6EB1-1109-48C4-BA32-9EBBCE574AC7Q46360744-2BB41B7B-2DD5-4C24-89FC-34D4A9061AE7Q47124054-102ADA80-AD44-4A6A-936D-9FA51471419AQ47574122-B64A91F9-AC23-4C34-A3AC-CD633F1A0838Q47767201-88893116-E21C-4A58-B43C-9213EFF1804FQ48231295-800485E8-50D6-4B7F-98EE-B8D36AEB0838Q48500283-C2C996F6-C32A-4BF8-AAEF-70F2275E2688Q49645159-A214E580-5353-4526-BD9E-27D358D486BDQ49956245-36EC729D-4729-4122-AA5F-1BCAE16C1754Q50345931-0BB8F37D-857F-49C6-860E-C48C09E84B41Q52345422-E0C2A7B6-7D49-4053-80C8-5AE3D82581E1Q52653002-0D84745D-9BA3-417D-88DD-90FE3F673C00Q52780295-41B08551-452A-492E-88F5-3C777607ADD8Q53776017-DA54E273-7846-415A-82AB-738C2778115BQ54995746-5D8FA402-B7BE-4BE6-AD6C-2391DDF7F295Q55230293-EAC07E9B-4082-46B9-AA6B-8F05B3E25A47Q55314165-A27D27BE-AB3D-449C-B0C9-805DDA58BE25Q55317607-8012DEB9-C63F-4FD9-B593-95B016FCBF32Q55401599-4FE3F158-835A-45FB-B8C5-238D675DBBC1Q57177486-B41624BD-0462-455B-BF4C-7618765C90C1
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Osimertinib: First Global Approval.
@ast
Osimertinib: First Global Approval.
@en
Osimertinib: First Global Approval.
@nl
type
label
Osimertinib: First Global Approval.
@ast
Osimertinib: First Global Approval.
@en
Osimertinib: First Global Approval.
@nl
prefLabel
Osimertinib: First Global Approval.
@ast
Osimertinib: First Global Approval.
@en
Osimertinib: First Global Approval.
@nl
P2860
P3181
P1433
P1476
Osimertinib: First Global Approval.
@en
P2093
Sarah L Greig
P2860
P2888
P304
P3181
P356
10.1007/S40265-015-0533-4
P577
2016-02-01T00:00:00Z
P6179
1049881407